| Literature DB >> 28777501 |
Mariarosa Mazza1, Neus Lozano1, Debora Braga Vieira1, Maurizio Buggio1, Cay Kielty2, Kostas Kostarelos1.
Abstract
Direct labeling of human mesenchymal stem cells (hMSC) prior to transplantation provides a means to track cells after administration and it is a powerful tool for the assessment of new cell-based therapies. Biocompatible nanoprobes consisting of liposome-indocyanine green hybrid vesicles (liposome-ICG) are used to safely label hMSC. Labeled hMSC recapitulating a 3D cellular environment is transplanted as spheroids subcutaneously and intracranially in athymic nude mice. Cells emit a strong NIR signal used for tracking post-transplantation with the IVIS imaging system up to 2 weeks (subcutaneous) and 1 week (intracranial). The transplanted stem cells are imaged in situ after engraftment deep in the brain up to 1 week in living animals using optical imaging techniques and without the need to genetically modify the cells. This method is proposed for efficient, nontoxic direct cell labeling for the preclinical assessment of cell-based therapies and the design of clinical trials, and potentially for localization of the cell engraftment after transplantation into patients.Entities:
Keywords: cell tracking; intracranial; liposomes; mesenchymal stromal cells; spheroids; subcutaneous
Mesh:
Substances:
Year: 2017 PMID: 28777501 DOI: 10.1002/adhm.201700374
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933